Previous close | 1.0000 |
Open | 1.0000 |
Bid | 1.1500 |
Ask | 1.4000 |
Strike | 2.50 |
Expiry date | 2024-12-20 |
Day's range | 1.0000 - 1.1500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new studies presented this past weekend at the 84th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando. The first study provides an analysis of member data for those tracking a GLP-1 medication in Dario's cardiometabolic solution.
DarioHealth Corp. (Nasdaq: DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitability.
Discover how DarioHealth Corp (DRIO) is shaping its future with significant B2B2C growth, high gross margins, and strategic partnerships in the first quarter of 2024.